Quick Take
Clinical stage biopharmaceutical company Biohaven Pharmaceuticals (Pending:BHVN) has filed to raise $125 million in an IPO by selling 8.33 million common shares at a midpoint price of $15.00 per share.
Biohaven has a large pipeline of treatments under development for neurological conditions.
The company is in or nearing Phase 3 trials for its lead candidates, but faces strong competition from other new treatments and must pay significant milestone and royalty payments for its candidates.
